【先声药业：英沐乐获批上市，150天保护效力85.32%】先声药业公告，公司此前与瑞阳生物达成战略合作，获得英沐乐在大中华区的独家商业化权益。2026年9月3日，库莱韦拜单抗注射液获国家药品监督管理局批准在中国上市，用于预防新生儿和婴儿感染RSV引起的下呼吸道感染。关键性III期研究显示，给药后150天保护效力为85.32%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.